Gubra – Presentation of Q3 2024

Meet and ask questions to Gubra’s management – CEO Henrik Blou and CFO Kristian Borbos on 7 November at 12.00 PM when they present the Q3 report 2024.

Focus will be on Q3 report and the underlying growth in the CRO business area. Besides that, we expect an update on potential triggers in the D&P pipeline.

Gubra, founded in 2008 in Denmark, is specialized in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases. Gubra’s activities are focused on the early stages of drug development and are organized in two business areas - CRO Services and Discovery & Partnerships (D&P). The two business areas are highly synergistic and create a unique entity capable of generating a steady cash flow from the CRO business while at the same time enjoying biotechnology upside in the form of potential development milestone payments and potential royalties from the D&P business. Gubra has approx. 200 employees and had annual revenue of above DKK 200 million in 2023. See www.gubra.dk for more information. Gubra is listed on Nasdaq Copenhagen mid Cap, with ticker code: GUBRA.

Disclaimer: HC Andersen Capital receives payment from Gubra for a Digital IR/Corporate Visibility agreement./Claus Thestrup 10 October 2024 at 13.42.